GlassScriptPhysician profile
Ariel C Ponce
NPI 1164458592
$9,961.35
in general payments reported to CMS, 2019-2025
37 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $952 · 2021: $1,324 · 2022: $1,873 · 2023: $1,557 · 2024: $1,920 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,168.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,449.49 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,192.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $918.55 | 2021-2025 | |
| Amgen INC. | $801.72 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $801.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $692.04 | 2019-2025 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $567.08 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $520.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $446.33 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $328.86 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $287.73 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $265.00 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Exact Sciences Corporation | $247.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $243.89 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $175.22 | 2020-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Ponce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.